hsq96 pyrosequencer (BIOTAGE)
90
Structured Review
BIOTAGE
hsq96 pyrosequencer
Hsq96 Pyrosequencer, supplied by BIOTAGE, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pyrosequencing+pyrosequencer/hsq96+pyrosequencer/pmc04186640-27-18-20
Average 90 stars, based on 1 article reviews
Hsq96 Pyrosequencer, supplied by BIOTAGE, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pyrosequencing+pyrosequencer/hsq96+pyrosequencer/pmc04186640-27-18-20
Average 90 stars, based on 1 article reviews
hsq96 pyrosequencer - by Bioz Stars,
2026-11
90/100 stars
Images
Related Articles
Mutagenesis:Article Title: Cytogenetic landscape and impact in blast phase of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Article Snippet: This is a PDF file of an unedited peer-reviewed manuscript that has been accepted for publication.. NPG are providing this early version of the manuscript as a service to our customers.. The manuscript will undergo copyediting, typesetting and a proof review before it is published in its final form. Article Title: Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors Article Snippet: .. 3 On follow-up samples, the ratio of F317L mutated to unmutated transcripts was performed by pyrosequencing using an Isolation:Article Title: Cytogenetic landscape and impact in blast phase of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Article Snippet: This is a PDF file of an unedited peer-reviewed manuscript that has been accepted for publication.. NPG are providing this early version of the manuscript as a service to our customers.. The manuscript will undergo copyediting, typesetting and a proof review before it is published in its final form. Article Title: Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy Article Snippet: For analysis of T315I in follow-up samples, pyrosequencing was performed following this first-round PCR. .. PCR was performed using one biotin-tagged primer, with single-stranded PCR product isolated on strepavidin-sepharose beads (GE Healthcare, Little Chalfont, United Kingdom) and sequenced using nucleotide dispensation tips and Pyro Gold reagents on a Article Title: Kinase Domain Point Mutations in Ph+ Acute Lymphoblastic Leukemia (ALL) Emerge Following Therapy with BCR-ABL Kinase Inhibitors Article Snippet: For mutation analysis of codons 311-317 and codons 250-255, pyrosequencing was performed following first round PCR, as above and different 2 nd -round PCR reactions. .. Second round PCR was performed using one biotin-tagged primer and single-stranded product isolated by avidin-sepharose beads (GE Life Sciences, Piscataway, NJ) and sequenced using a Article Title: Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation treated in the pre- and post-ponatinib era. Article Snippet: Funding information National Institutes of Health; MD Anderson's Cancer Center Leukemia SPORE, Grant/Award Number: CA100632; Cancer Center Support Grant (CCSG), Grant/Award Number: P30CA016672; Charif Souki Cancer Research Grant Abstract Patients with chronic myeloid leukemia (CML) and T315I mutation generally have a poor prognosis.. Their outcome in the post-ponatinib era remains unclear.. We reviewed patients with CML in chronic (CP) or accelerated phase (AP) who developed a T315I mutation between March 15, 2004, and July 26, 2022. Article Title: Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation treated in the pre- and post-ponatinib era Article Snippet: For analysis of T315I in follow-up samples, pyrosequencing was performed following this first-round PCR. .. PCR was performed using one biotin-tagged primer, with single-stranded PCR product isolated on strepavidin-sepharose beads (GE Healthcare, Little Chalfont, United Kingdom) and sequenced using nucleotide dispensation tips and Pyro Gold reagents on a Article Title: Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations Article Snippet: For analysis of follow-up samples, pyrosequencing was performed after first-round PCR (as mentioned earlier in this paragraph). .. PCR was performed using one biotin-tagged primers, single-stranded PCR product isolated on strepavidin sepharose beads (GE Healthcare), and sequenced using nucleotide dispensation tips and Pyro Gold reagents on a Avidin-Biotin Assay:Article Title: Cytogenetic landscape and impact in blast phase of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Article Snippet: This is a PDF file of an unedited peer-reviewed manuscript that has been accepted for publication.. NPG are providing this early version of the manuscript as a service to our customers.. The manuscript will undergo copyediting, typesetting and a proof review before it is published in its final form. Article Title: Kinase Domain Point Mutations in Ph+ Acute Lymphoblastic Leukemia (ALL) Emerge Following Therapy with BCR-ABL Kinase Inhibitors Article Snippet: For mutation analysis of codons 311-317 and codons 250-255, pyrosequencing was performed following first round PCR, as above and different 2 nd -round PCR reactions. .. Second round PCR was performed using one biotin-tagged primer and single-stranded product isolated by avidin-sepharose beads (GE Life Sciences, Piscataway, NJ) and sequenced using a Polymerase Chain Reaction:Article Title: Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy Article Snippet: For analysis of T315I in follow-up samples, pyrosequencing was performed following this first-round PCR. .. PCR was performed using one biotin-tagged primer, with single-stranded PCR product isolated on strepavidin-sepharose beads (GE Healthcare, Little Chalfont, United Kingdom) and sequenced using nucleotide dispensation tips and Pyro Gold reagents on a Article Title: Kinase Domain Point Mutations in Ph+ Acute Lymphoblastic Leukemia (ALL) Emerge Following Therapy with BCR-ABL Kinase Inhibitors Article Snippet: For mutation analysis of codons 311-317 and codons 250-255, pyrosequencing was performed following first round PCR, as above and different 2 nd -round PCR reactions. .. Second round PCR was performed using one biotin-tagged primer and single-stranded product isolated by avidin-sepharose beads (GE Life Sciences, Piscataway, NJ) and sequenced using a Article Title: Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation treated in the pre- and post-ponatinib era. Article Snippet: Funding information National Institutes of Health; MD Anderson's Cancer Center Leukemia SPORE, Grant/Award Number: CA100632; Cancer Center Support Grant (CCSG), Grant/Award Number: P30CA016672; Charif Souki Cancer Research Grant Abstract Patients with chronic myeloid leukemia (CML) and T315I mutation generally have a poor prognosis.. Their outcome in the post-ponatinib era remains unclear.. We reviewed patients with CML in chronic (CP) or accelerated phase (AP) who developed a T315I mutation between March 15, 2004, and July 26, 2022. Article Title: Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation treated in the pre- and post-ponatinib era Article Snippet: For analysis of T315I in follow-up samples, pyrosequencing was performed following this first-round PCR. .. PCR was performed using one biotin-tagged primer, with single-stranded PCR product isolated on strepavidin-sepharose beads (GE Healthcare, Little Chalfont, United Kingdom) and sequenced using nucleotide dispensation tips and Pyro Gold reagents on a Article Title: Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations Article Snippet: For analysis of follow-up samples, pyrosequencing was performed after first-round PCR (as mentioned earlier in this paragraph). .. PCR was performed using one biotin-tagged primers, single-stranded PCR product isolated on strepavidin sepharose beads (GE Healthcare), and sequenced using nucleotide dispensation tips and Pyro Gold reagents on a other:Article Title: Stem cell transplantation for patients with chronic myeloid leukemia resistant to tyrosine kinase inhibitors with BCR-ABL kinase domain mutation T315I. Article Snippet: Quantification of the T315I mutation was performed by pyrosequencing with a similar Nested PCR:Article Title: Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors Article Snippet: .. 3 On follow-up samples, the ratio of F317L mutated to unmutated transcripts was performed by pyrosequencing using an |